Unlike common nutraceuticals stocked in every health store, CJC-1295 is distributed via a dedicated online market that Agost residents access almost entirely online. What this means for Agost researchers is that geography is secondary to your ability to verify analytical documentation — and those quality checks are within reach of all serious researchers. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. What follows is a vendor evaluation and quality guide built specifically around CJC-1295, covering everything a Agost researcher needs to source confidently.
How CJC-1295 Works — Mechanisms & Research
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Agost researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade CJC-1295
Quality CJC-1295 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are signalling genuine quality commitment. The HPLC purity trace is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with minimal secondary peaks representing impurities — purity should be at or above 98%. Community reputation in research forums is a complementary signal to COA verification — vendors with multi-year positive track records have proved themselves through consistent results. For Agost researchers making a first CJC-1295 purchase: work through this evaluation framework first, begin with a small order, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Agost
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not completed the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution stored refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with sterile bacteriostatic water. Endotoxin testing in the CJC-1295 COA is absolutely required — gram-negative bacterial endotoxins can trigger dangerous immune responses at minute levels, and no discount compensates for this missing data. The research literature on CJC-1295 should be studied thoroughly before beginning any research — study designs, dosing ranges, and outcome measures vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
